Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer, meeting 1 of the following stage criteria:~  * Stage IIIB disease with malignant pericardial or malignant pleural effusions, as indicated by 1 of the following:~    * Positive cytology~   * Exudative effusion AND lactic dehydrogenase (LDH) \> 200 IU with effusion/serum LDH ratio ≥ 0.6~ * Stage IV disease~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques OR \> 10 mm by spiral CT scan~* Brain metastases allowed provided they have been irradiated AND are radiographically stable for ≥ 28 days after the completion of radiotherapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* At least 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL~Hepatic~* AST and ALT normal~* Bilirubin normal~Renal~* Creatinine clearance ≥ 50 mL/min~Immunologic~* No known HIV positivity~* No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* No clinically significant active infection~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception before, during, and for 4 weeks after completion of study treatment~* No other primary malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix~* No other serious systemic disorder that would preclude study participation~* No other condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior antibody-based therapy that targets growth factor pathways (e.g., epidermal growth factor receptor \[EGFR\]) allowed provided there is disease progression during therapy and patient has recovered~* No concurrent immunotherapy~* No concurrent prophylactic colony-stimulating factors~* No concurrent interleukin-11~Chemotherapy~* No prior cytotoxic chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy for the malignancy~Radiotherapy~* See Disease Characteristics~* More than 28 days since prior radiotherapy and recovered~* No prior radiotherapy to ≥ 25% of the bone marrow~* No prior radiotherapy to sites of measurable disease unless there is documented tumor progression after completion of radiotherapy~* No concurrent radiotherapy~Surgery~* No concurrent surgery for the malignancy~Other~* More than 3 weeks since prior investigational drugs~* Prior oral small molecule drug therapy that targets growth factor pathways (e.g., EGFR) allowed provided there is disease progression during therapy and patient has recovered~* No other concurrent investigational or commercial agents or therapies for the malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Docetaxel and Cisplatin (Type: EXPERIMENTAL): A cycle is defined as an interval of 28 days.~Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).~Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).~Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues